Citations

Clear

2369 citation(s) found for "Su, Jack".

Co‐pathologies and biological processes beyond amyloid‐beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies
Ferreira, Daniel, Chmiela, Tomasz , Eriksdotter, Maria, Jack, Clifford R., Marseglia, Anna , Mecocci, Patrizia , Nordberg, Agneta, Westman, Eric, Marseglia, Anna , Mecocci, Patrizia , Chmiela, Tomasz , Ferreira, Daniel , Eriksdotter, Maria , Jack, Clifford R. , Kalpouzos, Grégoria , Nordberg, Agneta , Religa, Dorota , Westman, Eric

Mayo Clinic

Journal of Internal Medicine | April 16, 2026 | Volume: 299 | Issue: 6 | Pages: 694-710

10.1111/joim.70096 | PMID 41988825 Get It

Abstract Alzheimer's disease (AD) is neuropathologically defined by amyloid‐beta (Aβ) plaques and tau neurofibrillary tangles. However, co‐pathologies and other pathobiological processes are involved in the pathogenesis of AD, contributing to neurodegeneration and clinical symptoms. The most common co‐pathologies in people with AD are alpha‐synucleinopathy, vascular brain injury and transactive response DNA‐binding protein of 43 kDa‐related pathology. Neuroinflammation, iron accumulation, cholinergic dysfunction and cellular senescence are recognized pathobiological processes beyond Aβ‐ and tau‐related pathology. However, the exact mechanisms by which these co‐pathologies and pathobiological processes contribute to the neurodegeneration and clinical symptoms in people with AD remain unclear. The individual combination of these co‐pathologies and pathobiological processes increases phenotypical heterogeneity in people with AD. This highlights the unmet need to advance their current understanding, and the field strives to develop accurate biomarkers for personalized assessment and investigation. Elucidating this biologic‐clinical complexity and heterogeneity is crucial for increasing our current understanding of AD, with implications for diagnosis, prognosis and therapeutics.
Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis
Azzam, Muayad , Hamarsha, Qais , Kawtharany, Hassan , Nazzal, Jamil, Alkhader, Aseel, Khraise, Tala, AlMasri, Mohammad M., Zeid, Hadi K. Abou, Alwan, Iktimal, Jaber, Nour, Seftel, Matthew D. , Aguirre, M A, Boedicker, Deborah , Bumma, Naresh , Comenzo, Raymond, Dasgupta, Noel R, Torre, Alfredo De La, Jamal, Faizi , Khouri, Jack , Raza, Shahzad, Sarswat, Nitasha , Shaikh, Hira , Singh, Daulath , Kukreti, Vishal, Zeid, Hadi Khaled Abou , Aguirre, María Adela , Abou Zeid, Hadi Khaled , Aguirre, Maria Adela , Carroll, Antonia S , Cook, Joselle M , Dispenzieri, Angela , Jamal, Faizi , Khouri, Jack , Picken, Maria M. , Leung, Nelson , Sanchorawala, Vaishali , Sarswat, Nitasha , Mustafa, Reem A , Kawtharany, Hassan , Shaikh, Hira , Carroll, Antonia , Comenzo, Raymond L. , Cook, Joselle , Dispenzieri, Angela , Raza, Shahzad, Leung, Nelson , Kukreti, Vishal

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5293-5307

10.1182/bloodadvances.2025019530 | PMID 41979328 Get It

Abstract In this systematic review, we aimed to assess the sensitivity of serum immunofixation (SIFE), urine immunofixation (UIFE), and serum free light chain (sFLC) in detecting plasma cell dyscrasia associated with light chain (AL) amyloidosis. We searched the literature using PubMed, Embase, and CENTRAL databases since inception through March 2024. We included studies reporting the diagnostic accuracy of immunofixation and/or sFLC in patients with AL amyloidosis. We used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach to assess the certainty of the evidence and QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2) to assess the risk of bias. After deduplication, 29 237 records were screened, and 44 studies (n = 18 071) were included. For the meta-analysis, 28 studies reported sensitivity for SIFE (n = 3390), 24 studies for UIFE (n = 2830), 19 studies for SIFE and UIFE (n = 2819), 21 studies for sFLC ratio (n = 3678), 6 studies for SIFE and sFLC ratio (n = 372), 3 studies for UIFE and sFLC ratio (n = 242), and 10 studies for all 3 tests (n = 1430). Pooled sensitivities were as follows: SIFE, 0.68 (95% confidence interval [CI], 0.62-0.73); UIFE, 0.77 (95% CI, 0.72-0.81); SIFE and UIFE, 0.89 (95% CI, 0.84-0.93); and sFLC ratio, 0.82 (95% CI, 0.78-0.86). When SIFE, UIFE, and sFLC ratio were combined, the sensitivity reached 0.99 (95% CI, 0.96-1.00). The high sensitivity of combining SIFE, UIFE, and sFLC ratio supports their use as a reliable initial testing strategy to raise suspicion for AL amyloidosis and guide decisions regarding future diagnostic modalities.
Transcriptional and spatial profiling of fibroblasts from human lungs highlights CTHRC1+ cells as fibrogenic signaling hubs in fibrosis
Vanegas-Avendano, Natalia Del Pilar, Ghobashi, Ahmed, Sen, Chandani , Reader, Brenda F. , Gomperts, Brigitte N. , Ma, Qin, Tschumperlin, Daniel J. , Rojas, M. Montelongo, Vanegas-Avendaño, Natalia, Chen, H., Wellmerling, Jack , Rodriguez-Lopez, Jhonny , Ghobashi, Ahmed, Peters, Victor , Shilo, Konstantin , Mora, Ana Lucia , Rojas, Mauricio M.

Mayo Clinic

No container title available | April 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.08.717092 | PMID 41993306 Get It

Abstract Lung fibroblasts are key regulators of tissue homeostasis and extracellular matrix (ECM) remodeling, and their aberrant activation drives the progressive parenchymal scarring characteristic of idiopathic pulmonary fibrosis (IPF), a fatal disease with limited therapeutic options. Despite their central pathogenic role, lung fibroblasts are difficult to isolate due to their embedded position within the ECM, and standard in vitro culture conditions may lead to the loss of their native functional and transcriptional characteristics, hampering the study of fibroblast behavior in disease. The transcriptional heterogeneity of lung fibroblast subtypes and the extent to which culture-induced alterations diverge from native tissue signatures remain poorly understood. Here, we integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics of lung tissue from IPF patients and age-matched healthy donors with transcriptomic profiling of cultured fibroblasts collected at passages 1 and 6 after isolation using three optimized protocols: whole lung cell suspension (WLCS), negative fraction enrichment, and outgrowth. Tissue-based analysis identified six transcriptionally distinct mesenchymal subtypes: alveolar, adventitial, inflammatory, peribronchial, CTHRC1+ and smooth muscle cell (SMC). The fibroblast subtype CTHRC1+ represented the most transcriptionally activated pro-fibrotic subtype, showing the greatest upregulation of ECM biosynthesis genes, a prominent role in intercellular communication, and preferential enrichment within fibroblastic foci in IPF lung tissue. Pseudotime trajectory analysis supported a directional transcriptional continuum from alveolar and inflammatory fibroblasts toward the CTHRC1+ state, driven by coordinated activation of pro-fibrotic transcription factors, including RUNX2, CREB3L1, and SCX. In vitro culture progressively reshaped fibroblast transcriptional identity relative to native tissue, with increased collagen and matrix metalloproteinase (MMP) expression during passaging, loss of distinct CTHRC1+ fibroblasts, and gain of alveolar fibroblasts displaying pro-fibrotic activation across all isolation protocols. These findings provide a high-resolution transcriptional map of lung fibroblast heterogeneity in IPF and highlight critical limitations of standard in vitro culture systems for recapitulating native fibroblast diversity, with important implications for the development and evaluation of fibroblast-targeted therapeutic strategies in IPF.
PFT Corner #14 Surgical Resection for Bullous Emphysema
Wanger, Jack, Irvin, Charles G. , Peters, Steve G. , Staats, Bruce A.

Mayo Clinic

Respiratory Care | April 10, 2026 | Volume: 30 | Issue: 2 | Pages: 122-124

10.1177/194336548503000206 Get It

PFT Corner #8
McCloskey, Timothy J, Enright, Paul, Wanger, Jack, Irvin, Charles

Mayo Clinic

Respiratory Care | April 10, 2026 | Volume: 29 | Issue: 4 | Pages: 400-402

10.1177/194336548402900412 Get It

Biochemical and Immunohistochemical Associations of TDP ‐43 and Cryptic RNA With Hippocampal and Amygdala Volumetrics in Alzheimer's Disease
Gatto, Rodolfo G. , Ghayal, Nikhil B , Ayuso, Virginia Estades, Jansen‐West, Karen , Dunmore, Judith A. , Song, Yuping , Yue, Mei, Cook, Casey , DeTure, Michael , Rawlinson, Bailey, Castanedes‐Casey, Monica, Jack, Clifford R., Petersen, Ronald C. , Petrucelli, Leonard, Whitwell, Jennifer L. , Prudencio, Mercedes , Josephs, Keith A. , Youseff, Hossam , Ghayal, Nikhil B , Estades Ayuso, Virginia , Rawlinson, Bailey D, Petersen, Ronald C , Dickson, Dennis W , Whitwell, Jennifer , Josephs, Keith A , Prudencio, Mercedes , Whitwell, Jennifer L , Youssef, Hossam , Castanedes‐Casey, Monica , Jack, Clifford R. , Dickson, Dennis W. , Petrucelli, Leonard

Mayo Clinic

Annals of Neurology | April 9, 2026 | Volume: 100 | Issue: 1 | Pages: 193-205

10.1002/ana.78223 | PMID 41952326 Get It

Objective Immunohistochemically (IHC) measured transactive response DNA‐binding protein 43 (TDP‐43) inclusions are observed in Alzheimer's disease (AD) and are associated with medial temporal lobe atrophy. Accumulation of cryptic exons occurs in AD in response to TDP‐43 pathology. We aimed to assess relationships between IHC and biochemically measured insoluble TDP‐43 and cryptic exons and assess associations with hippocampal and amygdala volume loss and atrophy rates on magnetic resonance imaging (MRI). Methods Eighty‐one neuropathologically diagnosed AD cases were analyzed. For biochemistry, insoluble TDP‐43 was quantified using a Meso‐scale discovery (MSD) immunoassay. IHC‐TDP burden was quantified with digital histopathology. Cryptic RNAs were assessed via quantitative real‐time polymerase chain reaction (qRT‐PCR). Thirty‐eight cases had serial brain MRI. Hippocampal and amygdala volumes were calculated using FreeSurfer. Regression models were used to investigate associations among IHC‐TDP‐43 status/burden, MSD‐TDP status/levels, cryptic RNAs, and hippocampal and amygdala volumes and atrophy rates. Results IHC‐TDP(+) cases exhibited elevated levels of MSD‐TDP and cryptic RNAs ( KCNQ2 , STMN2 , and UNC13A ) and increased MSD‐TDP levels were associated with increased cryptic RNA levels, in the hippocampus and amygdala. IHC‐TDP(+) cases had smaller hippocampal and amygdala volumes compared to IHC‐TDP(−) cases. MSD‐TDP(+) cases had smaller hippocampal volumes and faster amygdala rates of atrophy compared with MSD‐TDP(−) cases. Higher KCNQ2 and UNC13A levels were associated with smaller amygdala volumes. Interpretation MSD‐TDP level is a reliable surrogate for IHC‐based TDP‐43 status. Both TDP‐43 and cryptic RNA levels are associated with reduced medial temporal volumes, suggesting cryptic exons may be playing a role in brain volume loss in AD. ANN NEUROL 2026;100:193–205
Myeloperoxidase promotes fibrosis by inhibiting cathepsin K to bias the lung toward ECM accumulation
Link, Patrick A. , Meridew, Jeffrey A., Naoi, Hyogo, Rojas, M. Montelongo, Carmona, Eva M. , Tschumperlin, Daniel J. , Wellmerling, Jack , Tschumperlin, Daniel J , Carmona, Eva M , Link, Patrick A , Prakash, Y. S. , Rojas, Mauricio M.

Mayo Clinic

No container title available | April 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.05.713467 | PMID 41993445 Get It

Abstract Pulmonary fibrosis (PF) involves excessive collagen accumulation, yet mechanisms shifting the balance of synthesis and degradation toward net deposition remain unclear. Myeloperoxidase (MPO) inversely correlates with survival in PF. Using the bleomycin model, we found MPO knockout (MPOko) mice were protected from fibrosis, and pharmacological MPO inhibition after peak inflammation (day 7) recapitulated this protection. MPO persisted in lung tissue 21 days post-injury despite neutrophil efflux, linking acute inflammation to sustained remodeling. Mechanistically, we identified that MPO inhibits Cathepsin K (CatK), a potent collagenolytic enzyme involved in fibrosis resolution. Notably, CatK gene expression ( CTSK ) is elevated in PF, suggesting post-translational inhibition of CatK. MPOko and inhibitor-treated mice exhibited elevated CatK activity after bleomycin; exogenous addition of pathophysiologic concentrations of MPO reduced CatK activity in mouse precision-cut lung slices and human fibroblasts. Biochemically, MPO reduced CatK activity to 33% of control. In two distinct cohorts of PF patients, we observed significantly increased MPO protein levels in platelet poor plasma and in lung tissue. In PF patients, 62% had MPO levels in platelet poor plasma exceeding healthy controls, while lung tissue from other PF patients showed significantly elevated MPO staining. Plasma levels were inversely correlated with decreased survival, FVC, and DLCO. These findings establish MPO as a post-translational inhibitor of CatK-mediated collagenolysis, revealing a mechanism linking acute inflammation to sustained fibrosis and suggest a patient subpopulation that may benefit from MPO-targeted therapy. Graphical Abstract Myeloperoxidase persists in lung tissue after injury and inhibits cathepsin K activity, impairing collagen degradation and promoting extracellular matrix accumulation during pulmonary fibrosis.
Multi-Contrast MRI Inputs Enable Self-Consistent Tissue Segmentation & Robust Perivascular Space Identification
Gunter, Jeffrey L. , Preboske, Gregory M., Persons, Benjamin D., Przybelski, Scott A. , Petersen, Ronald, Jack, Clifford R, Gunter, Jeffrey L , Persons, Benjamin, Schwarz, Christopher G. , Low, Audrey , Vemuri, Prashanthi , Jack, Clifford R.

Mayo Clinic

No container title available | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.03.716409 | PMID 41993560 Get It

Abstract Different MRI image contrasts are designed to highlight various tissue properties and combining them allows extension of probabilistic segmentation beyond the commonly used “gray-white-CSF” models. This work describes a fully automated method that combines T1-weighted, T2-FLAIR, and conventional T2-weighted images to provide internal consistency across prediction of tissue segmentations including segmentation of superficial and deep gray matter, white matter hyperintensities, and MR-visible perivascular spaces. Results from 773 imaging datasets from 403 participants in the Mayo Clinic Study of Aging and Mayo Clinic Alzheimer’s Disease Research Center (ADRC) are presented.
Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging
Hu, Mingzhao, Knopman, David S., Therneau, Terry, Fought, Angela J. , Hofrenning, Ekaterina I. , Lowe, Val J., Petersen, Ronald C., Jack, Clifford R., Mielke, Michelle M., Vemuri, Prashanthi, Graff‐Radford, Jonathan, Hofrenning, Ekaterina, Graff-Radford, Jonathan , Hu, Mingzhao, Knopman, David S. , Therneau, Terry, Lowe, Val J. , Petersen, Ronald C. , Algeciras‐Schimnich, Alicia , Jack, Clifford R. , Stricker, Nikki H. , Mielke, Michelle M. , Vemuri, Prashanthi , Graff‐Radford, Jonathan

Mayo Clinic

Alzheimer's & Dementia | April 7, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71227 | PMID 41944335 Get It

Abstract INTRODUCTION We examined when Alzheimer's disease biomarkers become informative by identifying age‐related breakpoints with slope‐changing trajectories. METHODS In 2082 Mayo Clinic Study of Aging participants, we modeled plasma amyloid beta (Aβ)42/40, phosphorylated tau (p‐tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), amyloid/tau positron emission tomography (PET), hippocampal volume (HVa), and global cognition. Generalized additive models described age trends; Davies' test and piecewise linear regression estimated breakpoints. A C2N subsample ( n = 462) provided mass‐spectrometry plasma markers (p‐tau181, p‐tau217, their ratios, Aβ42/40). RESULTS In the full cohort, Aβ42/40, HVa, and cognition declined with age; p‐tau181, NfL, GFAP, and amyloid/tau PET increased. We observed single breakpoints (years, 95% CI): GFAP 68.1 (63.5–71.8), NfL 70.7 (65.9–75.6), p‐tau181 67.2 (60.3–70.3), amyloid PET 62.3 (56.2–69.3), HVa 68.1 (63.1–71.9), cognition 59.8 (55.4–66.0); tau PET showed none. In the mass‐spectrometry subset, p‐tau217 and p‐tau181 broke at 72.6; their ratios and Aβ42/40 showed no breakpoints. DISCUSSION Breakpoints cluster near late midlife, suggesting windows for screening and monitoring.
Abstract 3081: TEAD inhibition by IAG933 as a novel therapeutic strategy for cholangiocarcinoma
Nishi, Hidemi , Jessen, Erik , Carlson, Danielle M. , Abdelrahman, Amro , Ozmert, Enis H., Safi, J. Pedro Fincatto, Yee, Shelby K., Werneburg, Nathan W., Smoot, Rory L., Carlson, Danielle Marie , Safi, J. Pedro F., Wilbanks, Brandon , Sample, Jack W. , Smoot, Rory L.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 3081-3081

10.1158/1538-7445.am2026-3081 Get It

Abstract Background: Cholangiocarcinoma (CCA) is an aggressive hepatobiliary malignancy with marked molecular heterogeneity, limited systemic treatment options, and poor prognosis. Chemoresistance and KRAS mutations remain major therapeutic challenges. Dysregulation of the Hippo pathway, particularly YAP/TAZ hyperactivation, drives CCA progression and resistance. TEAD, the essential transcriptional partner of YAP/TAZ, represents a promising target. IAG933 is a novel oral pan-TEAD inhibitor designed to disrupt YAP/TAZ-TEAD interactions. RMC-6236, a pan-KRAS inhibitor, has also gained attention. Combined TEAD and KRAS inhibition may overcome resistance and improve efficacy in CCA. Methods: We evaluated IAG933 in human (HuCCT1, RBE) and murine (SB1, FAC) CCA cell lines. Cells were treated with IAG933 alone or in combination with GemCis or RMC-6236. Cell viability assays were used to determine IC50 values and calculate combination indexes (CI). TEAD activity was assessed by luciferase reporter and qRT-PCR of YAP/TAZ target genes (CTGF, CYR61, NUAK2). Transcriptomic alterations were analyzed by RNA sequencing. In vivo efficacy was evaluated in syngeneic orthotopic and patient-derived xenograft (PDX) models. Results: IAG933 suppressed TEAD-dependent transcription (IC50 ≈ 500 nM) and downregulated YAP/TAZ target genes. Combination with GemCis or RMC-6236 produced synergistic effects (CI < 1) in all CCA lines. Transcriptomic analysis revealed activation of oxidative stress response pathways, particularly SOD2 upregulation. MitoSOX staining confirmed increased mitochondrial ROS after treatment. In vivo, IAG933 monotherapy suppressed tumor growth similarly to GemCis. Dual TEAD and KRAS inhibition achieved marked tumor regression and significantly delayed tumor regrowth after treatment cessation in KRAS-mutant PDX models. Conclusion: IAG933 effectively suppresses YAP/TAZ-TEAD signaling and inhibits CCA growth. While the combination with GemCis showed limited additional benefit due to strong single-agent efficacy, synergy with RMC-6236 produced durable antitumor effects, particularly in run-out studies, delaying regrowth in KRAS-mutant models. These findings highlight IAG933 as a promising therapeutic candidate targeting the Hippo-TEAD pathway, with potential benefit in KRAS-mutant CCA. Citation Format: Hidemi Nishi,Erik Jessen,Danielle M. Carlson,Amro M. Abdelrahman,Enis H. Ozmert,J. Pedro Fincatto Safi,Brandon A. Wilbanks,Shelby K. Yee,Jack W. Sample,Nathan W. Werneburg,Rory L. Smoot. TEAD inhibition by IAG933 as a novel therapeutic strategy for cholangiocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3081.